Crystal Structure of the FLT3 Kinase Domain Bound to the Inhibitor Quizartinib (AC220)

More than 30% of acute myeloid leukemia (AML) patients possess activating mutations in the receptor tyrosine kinase FMS-like tyrosine kinase 3 or FLT3. A small-molecule inhibitor of FLT3 (known as quizartinib or AC220) that is currently in clinical trials appears promising for the treatment of AML....

Descripción completa

Detalles Bibliográficos
Autores principales: Zorn, Julie A., Wang, Qi, Fujimura, Eric, Barros, Tiago, Kuriyan, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383440/
https://www.ncbi.nlm.nih.gov/pubmed/25837374
http://dx.doi.org/10.1371/journal.pone.0121177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383440/
https://www.ncbi.nlm.nih.gov/pubmed/25837374
http://dx.doi.org/10.1371/journal.pone.0121177

Ejemplares similares